AMEGI: Mexico’s domestic generic firms under pressure



The head of the Mexican Association of Generic Manufacturers (AMEGI), Rafael Maciel, has provided details of recent changes and pressures in Mexico’s generics market. According to AMEGI data, the generics sector currently accounts for 35%-40% of Mexico’s USD 16 billion market currently. However, there has recently been a fall in usage of generic drugs in private-sector independent pharmacies, which make up 56% of total generic drug retail outlets, with a fall in usage from 15% to 13% of the total.

There is also now considerable uncertainty surrounding domestic generics manufacturers, after the government indicated that it was open to the idea of displacing their products by purchasing from foreign generics manufacturers. The issue was one factor in the delay to the recent national drug tender, and also contributed to 62% of tenders not being filled. Maciel predicts that pharmacies will become a more frequent site for purchases of generic prescription drugs as a result of lack of stock in hospitals. He also revealed that Mexican firms are currently considering expansion internationally in order to counter escape competitive local conditions, including markets in Central and South America. Companies

Maciel explains that the industry is already working on innovations in the face of the new competition represented by laboratories that manufacture outside of Mexico, the drop in sales in independent pharmacies and the strong competition of generics in the country in general. Other firms are also considering moving into biosimilars development for markets in the United States, Canada, and Europe, according to Maciel.


Reference:

Related news
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved local manufacturer Laboratorios Unidos’s Glucoglip (linagliptin), a first-mover generic version of Boehringer Ingelheim (BI)’s diabetes drug Trayenta.
According to GBI analysis, Colombia-based distributor Seven Pharma last week obtained registration approval from Chile’s Institute of Public Health (ISP) for India-based Hetero Labs’ antiretroviral Dolgavi (dolutegravir), a first-mover generic version of UK giant GlaxoSmithKline (GSK)’s Tivicay.
GBI analysis reveals that Chile’s Institute of Public Health (ISP) last week cleared Germany-based pharma major Merck’s Toreza (rosuvastatin calcium), a generic version of AstraZeneca’s antilipidemic Crestor.
Global generics specialist Actavis’s antifungal anidulafungin has been approved by Chile’s Institute of Public Health (ISP), becoming the first-mover generic competitor since the registration of Pfizer’s originator drug Ecalta 12 years ago, GBI analysis shows.
Argentina-based Elea-Phoenix saw its oncology drug Zalutex (enzalutamide), a generic version of Japan-based Astellas' Xtandi, cleared by Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT), GBI analysis reveals.
Recent news
The Brazil-based Institute of Technology and Pharmaceuticals (Farmanguinhos), the drug making unit of the Oswaldo Cruz Foundation (Fiocruz), has delivered its pilot batches of hyperprolactinemia (HPRL) treatment cabergoline, the result of a Productive Development Partnership (PDP) with compatriot laboratory Cristália that concluded this year.
Brazil’s National Health Surveillance Agency (ANVISA) this week granted registration approval to Eli Lilly’s biologic drug Emgality (galcanezumab-gnlm), as revealed by GBI analysis.
The new Science and Technology Innovation Board (STAR) hosted by the Shanghai Stock Exchange (SSE) opened for business on July 22.
Belgium-based UCB announced the market approval in China for Cimzia (certolizumab pegol), for the indication of moderate-to-severe rheumatoid arthritis (RA).
  • 1563867876525
  • China
  • Drug
Denmark-based diabetes specialist Novo Nordisk has invested MXN 400 million (USD 21 million) in clinical research in Mexico between 2014 and 2018, involving 1,200 patients in 21 trials.
The Shandong Centralized Drug Procurement platform released a notification in relation to public hospital drug and consumables procurement alliances.
The “4+7” volume-linked drug procurement pilot scheme introduced at the end of 2018 in 11 cities is set to be expanded to all regions of the country, following a meeting between the National Health Security Administration (NHSA) and industry stakeholders held last week.
  • 1563857070043
  • China
Analytics Snapshot


Analytics Snapshot